ZNF540 is a zinc finger transcription factor that functions as a transcriptional repressor in multiple cellular contexts. The protein contains 660 amino acids and localizes to both the nucleus and cytoplasm 1. Mechanistically, ZNF540 interacts with MVP, a MAPK scaffold protein, and inhibits transcriptional activities of the ERK signaling pathway by repressing SRE and ELK-1 dependent gene expression 1. This regulatory function is consistent with its characterized DNA-binding and RNA polymerase II-specific transcriptional activity. Clinically, ZNF540 has emerged as a significant biomarker in cancer prognosis. In clear cell renal cell carcinomas (ccRCCs), ZNF540 promoter hypermethylation is a hallmark feature of the CpG island methylator phenotype (CIMP), which characterizes aggressive tumors with significantly lower cancer-free and overall survival rates 2. ZNF540 methylation status provides prognostic utility, with criteria combining ZNF540 CpG sites achieving 100% sensitivity and specificity in distinguishing CIMP-positive from CIMP-negative ccRCCs 3. In head and neck squamous cell carcinomas, higher ZNF540 expression correlates with HPV infection and improved overall survival, suggesting a tumor-suppressive role 4. Additionally, ZNF540 was identified as a component of a prognostic model for bicalutamide resistance in prostate cancer 5, indicating broader relevance in endocrine therapy resistance.